Cannabis May Both Relieve MS Symptoms and Protect Nerve Cells From Damage
Beyond symptom relief, experimental evidence suggests cannabinoids may have neuroprotective properties that could slow multiple sclerosis disease progression.
Quick Facts
What This Study Found
The review examined two distinct roles for cannabinoids in MS. First, the established symptom-relief function: cannabis reduces limb spasticity by modulating excessive neuronal signaling, which led to cannabis-based medicines being approved for pain and spasticity in MS.
Second, and more novel, experimental studies revealed that cannabinoids may have neuroprotective effects that could slow disease progression and delay the onset of symptoms like spasticity. This dual potential, treating both symptoms and underlying disease, represented a significant shift in thinking about cannabinoids in MS.
Key Numbers
Cannabis-based medicines were approved for pain and spasticity in MS at the time of publication. Experimental evidence for neuroprotection came from multiple animal models of MS.
How They Did This
Review of preclinical data from animal models of MS, clinical evidence from human studies, and analysis of the endocannabinoid system biology relevant to MS. Covered both symptom management and neuroprotection research.
Why This Research Matters
Most MS treatments address either symptoms or disease progression, but rarely both. If cannabinoids can do both simultaneously, they could represent a uniquely valuable class of MS therapeutics. The neuroprotective potential is particularly important because progressive nerve damage is what drives long-term disability in MS.
The Bigger Picture
This review shifted the conversation about cannabis and MS from pure symptom management toward disease modification. If cannabinoids can protect nerve cells from the damage that drives MS progression, the clinical implications extend far beyond making patients more comfortable.
What This Study Doesn't Tell Us
The neuroprotective evidence came primarily from animal models, which do not perfectly replicate human MS. Translating neuroprotective effects from preclinical models to clinical benefit has historically proven very difficult in neurology. Long-term clinical data were lacking.
Questions This Raises
- ?Can the neuroprotective effects demonstrated in animal models be replicated in human MS patients?
- ?What doses and cannabinoid combinations would be needed for neuroprotection?
- ?Could early cannabinoid treatment delay disability progression in MS?
Trust & Context
- Key Stat:
- Cannabinoids showed both symptom relief and neuroprotective potential in MS models
- Evidence Grade:
- Review combining clinical evidence for symptom relief with preclinical evidence for neuroprotection.
- Study Age:
- Published in 2012. Research on cannabinoid neuroprotection in MS has continued, though clinical proof of disease modification remains elusive.
- Original Title:
- Potential control of multiple sclerosis by cannabis and the endocannabinoid system.
- Published In:
- CNS & neurological disorders drug targets, 11(5), 624-41 (2012)
- Authors:
- Pryce, Gareth(10), Baker, David(10)
- Database ID:
- RTHC-00606
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis slow down MS progression?
Animal studies suggest cannabinoids have neuroprotective properties that could slow nerve damage in MS. However, this has not yet been conclusively demonstrated in human clinical trials. The current approved use of cannabinoid medicines in MS is for symptom relief, particularly spasticity and pain.
How might cannabinoids protect nerve cells?
The endocannabinoid system appears to play a role in regulating inflammation and neuronal survival. Cannabinoids may reduce the excessive immune activity that damages nerve cell myelin in MS, while also directly supporting nerve cell survival through anti-inflammatory and antioxidant mechanisms.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00606APA
Pryce, Gareth; Baker, David. (2012). Potential control of multiple sclerosis by cannabis and the endocannabinoid system.. CNS & neurological disorders drug targets, 11(5), 624-41.
MLA
Pryce, Gareth, et al. "Potential control of multiple sclerosis by cannabis and the endocannabinoid system.." CNS & neurological disorders drug targets, 2012.
RethinkTHC
RethinkTHC Research Database. "Potential control of multiple sclerosis by cannabis and the ..." RTHC-00606. Retrieved from https://rethinkthc.com/research/pryce-2012-potential-control-of-multiple
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.